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A B S T R A C T   
In vitro cell studies of hydrophobic drugs face difficulties associated with their low aqueous solubility. To study 
poorly soluble drugs in bio-relevant media, solubilizing agents are frequently used to make stock solutions before 
final reconstitution in media. This results in drug concentrations that are not representative of in vivo conditions 
and may pose adverse effects on cells’ biological functions. This is especially true of typical hydrophobic stent 
coatings intended for vascular applications, where poor in vitro to in vivo correlation exists. To this end, a method 
for preparation of hydrophobic drug suspensions in bio-relevant media via stent conditioned media using 
paclitaxel (PTX) as a model drug is proposed. Since the drug is present as a suspension, this media was validated 
for its content uniformity and potency to induce formation of micronuclei, typical of cells undergoing prolonged 
mitotic arrest. Further, PTX uptake by endothelial cells was quantified and showed that the PTX stent condi-
tioned media (at a theoretical concentration of 100 μM) suppressed cellular growth equivalent to the 0.1 μM 
DMSO dissolved PTX.   
1. Introduction 
An ever-increasing number of new drugs in development are hy-
drophobic in nature (Kalepu and Nekkanti, 2015). The poor water sol-
ubility of these new therapeutic agents represents challenges not only 
for formulation strategies to increase bioavailability but also for study-
ing the solution behaviour in bio-relevant media and their bioactivity 
and cytotoxicity in in vitro assays during cell culture studies (Williams 
et al., 2013; Savjani et al., 2012). Solubilizers and surfactants are 
frequently used to increase the solubility of hydrophobic drugs (Kalepu 
and Nekkanti, 2015; Savjani et al., 2012). In cell culture assays, poorly 
soluble drugs are often pre-dissolved in organic solvents as concentrated 
stock solutions, most commonly in DMSO or other organic solvents, 
before dilution to working concentrations in a biologically relevant 
buffer (Williams et al., 2013). The in vitro evaluation of candidate drugs 
is typically conducted in aqueous biologic buffers and media. The type of 
evaluation depends on the tested hypothesis but may include enzyme 
inhibition studies, metabolic activity, maximum inhibitory concentra-
tion or cellular uptake studies, all relying on known concentrations of 
the tested drug to draw conclusions. 
The main, and the most apparent concern with fully dissolved hy-
drophobic drugs in vitro arises from artificially high quantities of dis-
solved drug acting on cells that is not representative of the true situation 
in vivo. Clofazamine, an antimicrobial agent typically dissolved in 
DMSO, exhibits excellent anti-mycobacterial activity in vitro, yet the 
clinical use is limited due to its hydrophobic nature (Cholo et al., 2012; 
Srivastava and Gumbo, 2018). This is because, drugs with poor aqueous 
solubility such as clofazimine and paclitaxel will bury themselves in the 
lipophilic tissues within the body thus decreasing their bioavailability 
while increasing bioaccumulation (Granada et al., 2014; Mansfield, 
1974). The less obvious concern is with drug carriers that are harmful 
themselves, as is the case where another hydrophobic antimicrobial 
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drug triclosan loses its activity when solubilized in most organic solvents 
due to a strong interaction with the solubilizing agents (Vandhana et al., 
2010; Young et al., 2002). Various carrier systems are utilized to 
improve the solubility of poorly soluble drugs, such as oils, surfactants, 
emulsifiers or solvents and co-solvents (Kumar et al., 2013). The prop-
erties of the carrier systems have also been shown to greatly influence 
the behaviour of the drug in vivo (Straubinger, 1995; Singla et al., 2002). 
For example, cremophor, an oil used in parenteral preparations for 
poorly soluble paclitaxel and doxorubicin, was found to alter the phar-
macokinetics of the drugs in mice (Williams et al., 2013). During in vitro 
tests, the use of appropriate experimental controls may account for the 
potential cytotoxic impact of the drug vehicles but may still hinder the 
study of the impact on the cell’s fundamental properties, e.g. where the 
use of drug carriers may lead to the disruption of tight junctions in cell 
monolayers during permeability studies (Shah et al., 2014). Similar 
cytotoxic effects on membrane diffusion, cell lysis and even hemody-
namic disturbances in vivo have been reported with the use of DMSO that 
is not recommended for parenteral formulations yet is a commonly used 
solvent in cell culture assays (Mottu et al., 2000). Taken together, the 
solution behaviour of poorly soluble drugs reconstituted in organic 
solvents is not representative of the true concentration in vivo. Although 
solubilisation of hydrophobic drugs provides a means of overcoming the 
challenges associated with its poor aqueous solubility and accurate 
quantification of concentration, direct solubilisation in a physiologically 
relevant medium offers the opportunity to more accurately represent its 
response following in vivo administration. This may be especially rele-
vant in applications such as drug-eluting stents and balloons, where a 
solid form of drug is coated on the stent surface. 
One of the widely used stent coatings is paclitaxel (PTX). PTX, a 
potent mitotic inhibitor, was originally isolated from the bark of Pacific 
yew tree Taxus brevifolia during the National Cancer Institute search for 
the next antineoplastic agents in the 1960s (Rowinsky, 1993; Huizing 
et al., 1995). PTX has extremely low solubility in aqueous media (1 μg/ 
ml in water at 37 ◦C with shaking) making it very difficult to quantify in 
solution (Gi et al., 2004). In the presence of endogenous compounds, 
cells and tissues in vivo, this solubility changes but animal and ex vivo 
models are cost consuming and may not always be available (Creel et al., 
2000). PTX, unlike other cytotoxic drugs that promote depolymerization 
of microtubules, exerts its unique mechanism of action by stabilizing 
microtubules. The PTX-induced polymerization of microtubules pre-
vents their disassembly during mitosis, leading to a cell division halt at 
the G2/M phase (Huizing et al., 1995; Wang et al., 2000). Due to its 
highly hydrophobic nature, and subsequent challenges in delivery, PTX 
for intravenous administration is formulated in the presence of the 
adjuvant Cremophor EL ®, a mixture of polyoxyethylated castor oil and 
dehydrated alcohol to increase its solubility (van Zuylen et al., 2001). 
While PTX hydrophobicity is a challenge in systemic delivery, it is 
suitable for local delivery due to strong tissue retention (Creel et al., 
2000). The lipophilic nature of PTX has been utilized in the design of 
drug-eluting stents and drug-eluting balloons; where a solid drug form is 
used as a coating to fight neointimal thickening by supressing smooth 
muscle cell proliferation (Axel et al., 1997). One such example is a self- 
expanding Zilver PTX vascular stent (Cook Medical) on a nitinol plat-
form containing a polymer free 3 μg/mm2 paclitaxel coating. Currently, 
PTX-cell interactions are studied in vitro by dissolution in DMSO or other 
organic solvents (Blagosklonny et al., 2006; Lavigne et al., 2010; Bol-
gioni et al., 2018), where concentrations of <0.2 μM, usually 0.01–0.1 
μM, and 0.1–10 μM have been established as low and high doses 
respectively, but concentrations as high as 30 μM have been tested 
(Wang et al., 2000). 
In this study, a method of stent conditioned media preparation for 
the in vitro assessment of hydrophobic drugs is proposed, using PTX as a 
model drug. Paclitaxel is released from the surface of Zilver PTX drug 
eluting stent into culture media and the stent conditioned media is then 
evaluated for content uniformity and biological activity via a compar-
ative study against a conventional reconstitution method in DMSO. 
Conditioned media containing free drug without any solvent carriers 
such as presented here could be used to evaluate stent coatings of 
existing or new hydrophobic agents and to determine the effect of 
different coating densities and production methods on cell biocompat-
ibility. Although, PTX is selected here as a model drug, the relevance of 
this method can be extended to other poorly soluble drugs with similar 
physicochemical properties such as sirolimus, another poorly soluble 
anti-proliferative agent used in drug eluting stent coatings (Parry et al., 
2005). 
2. Materials and methods 
2.1. Materials 
Mouse Cardiac Endothelial Cell Lines (MCEC) (CLU510) VH Bio, 
Rhodamine Phalloidine (R415) Invitrogen, Dulbecco’s Modified Eagle’s 
Medium (D5796), Fetal Bovine Serum (F7524), L-Glutamine (G7513), 
Penicilin/Streptomycin (P0781), 1× Trypsin-EDTA (T3924), Phosphate 
Buffer Saline (P3813), Thiazolyl Blue Tetrazolium Bromide (M5655) 
and DAPI (D9543) all from Sigma Aldrich. Vascular stents, Zilver® 
PTX® drug-eluting peripheral stents and paclitaxel powder, used 
throughout the study were kindly supplied by Cook Medical, Limerick, 
Ireland. All stents were of 40 mm length and 5 mm diameter with 3 μg/ 
mm2 paclitaxel coating, ethylene oxide sterilized and supplied in sealed 
sterile Tyvek pouches. 
2.2. Preparation of PTX stent conditioned media 
Paclitaxel coating was released from the stent surface following an 
approach similar to the ISO 10993-12 “Extractables/leachables Testing 
of Medical Devices”, specifically section 12 of the standard. Here, Zil-
ver® PTX® stent samples with 3 μg/mm2 paclitaxel coating equating to 
a total target dose of 429 μg were immersed in 5 ml of complete cell 
growth media in 15 ml centrifuge tubes followed by sonication for 10 
min to release the paclitaxel coating. Samples were then incubated at 
37 ◦C, 5% CO2 for 48 h. Following the incubation time, stents were 
discarded and the required volume of PTX stent conditioned media was 
used in cell assays. All PTX stent conditioned media was prepared 48 h in 
advance of the scheduled experiments. 
2.3. Cell culture 
Immortalized Mouse Cardiac Endothelial cells (MCEC) were used in 
this study. This cell line although it grows indefinitely, continues to 
display normal endothelial characteristics such as exhibiting contact 
inhibition, cellular markers, and tight intercellular junctions that are 
usually not seen in other endothelial cell lines. Therefore, it is a suitable 
model for studying endothelial cells’ physiology (Barbieri et al., 2008; 
Barbieri and Weksler, 2007; He et al., 2008). Cells were cultured in 
DMEM supplemented with 5% FBS and 1% Penicillin/Streptomycin in a 
5% CO2 incubator at 37 ◦C. Cells were passaged at 70–80% confluency 
in a dilution of 1:5 or 1:10, reaching 80% confluency after 2 days or 3 
days, respectively. 
2.4. Cell viability assays 
The effect of PTX stent conditioned media and DMSO reconstituted 
paclitaxel on cell viability was assessed using an MTT assay. Cells seeded 
in a 96-well plate at a concentration of 1 × 104/well were allowed to 
adhere overnight. The next day cells were treated with PTX stent 
conditioned media or DMSO reconstituted paclitaxel. After 48 h, the 
MTT reagent was added to samples for 2 h at 37 ◦C. The MTT formazan 
crystals were dissolved by solubilisation buffer (10% SDS in 0.01 M HCl) 
followed by further incubation for 4 h at 37 ◦C. Absorbance was read at 
570 nm using a microplate spectrophotometric reader. Cell viability was 
determined by comparing absorbance values of treated cells to 
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absorbance values of untreated control cells. A percentage reduction of 
cell viability relative to that of control cells was used to express the 
obtained data. 
2.5. Cell visualization and quantification 
Confocal fluorescent images were captured with ImageXpress Micro 
Spinning Disc Confocal Microscope, Molecular Devices. DAPI and TRITC 
filters were used to detect nuclei and f-actin (Phalloidin-Rhodamine), 
respectively. Emission spectra was used under default settings. Images 
were stored in TIFF file format and cellular analysis was performed in 
Image J. (https://imagej.nih.gov/ij/). 
2.6. HPLC separation conditions for paclitaxel samples 
The HPLC system used was an Agilent 1200 Infinity Series (Agilent 
Technologies, Palo Alto, USA) comprising: G1311B 1260 quaternary 
pump, G1329B 1260 ALS autosampler, G1316A 1260 TCC (thermo-
stated column compartment) and a G1365D 1260 MWD VL diode-array 
detector. The acquired data was processed with the Agilent OpenLAB 
CDS software. Chromatographic separations of Paclitaxel samples were 
achieved using an Agilent Poroshell 120 PFP (3 × 100 mm, 2.7 μm) 
column fitted with a UHPLC Poroshell 120 guard module (3 × 5 mm, 2.7 
μm). The system was maintained at 25 ◦C with a run time of 18 min. The 
mobile phase which comprised A: HPLC Analytical grade Acetonitrile 
(Fisher Scientific) and B: deionized water (A:B 13:87, v/v) was delivered 
to the column at a flow rate of 1 ml/min which yielded a column back 
pressure of ~260 bar. Samples were filtered through a 0.2 μm Nylon 
filter (Fisherbrand®). The volume of analyte injected was within the 
range of 0.5 to 10 μl. Column effluent was detected at a UV detector 
wavelength of 228 nm. 
2.7. PTX coating release consistency in culture media 
Zilver PTX stents were weighed out using a 5-decimal place balance 
to determine the total weight of stent with the paclitaxel coating. The 
stent conditioned media was then prepared as outlined in section 2.2. 
Following 48 h incubation, the stent was removed and washed in PBS 
and water to remove traces of media, dried in the oven at 45 ◦C for 30 
min and weighed out to determine the weight of the stent without the 
paclitaxel coating. The PTX stent conditioned media was centrifuged at 
15000 xg, then placed in the oven to evaporate the growth media at 
60 ◦C over 48 h. The solids collected at the bottom of the 15 ml conical 
tube were reconstituted in 1 ml of ethanol and HPLC analysis was run to 
quantify the quantity of released paclitaxel. Images of stent samples 
before and after stent conditioned media preparation were taken with 
optical reflection microscope with a dark field filter. 
2.8. PTX stent conditioned media content uniformity 
The content uniformity, thus potency reproducibility of the PTX stent 
conditioned media preparation was validated using two parameters; cell 
viability and variation in the nuclear perimeter. MCEC viability after 
treatment with 200 μl of the PTX stent conditioned media per sample 
was assessed across 25 samples with the use of an MTT assay at 48 h as 
described in section 2.4. The 25 samples, each 200 μl, represent the 
entire volume of the stent conditioned media preparation. In the second 
method, standard deviation of cells’ nuclear perimeter exposed to PTX 
stent conditioned media at 48 h was assessed. Here, MCEC samples 
alongside controls were seeded at a 20,000 cells/well seeding density of 
a 96-well plate and allowed to proliferate in a complete growth media 
overnight before incubation with 200 μl of PTX stent conditioned media 
for each cell sample and media changes for the controls. After 48 h in-
cubation both samples and the controls were fixed in 4% PFA for 15 min 
at RT, f-actin filaments were stained with Phalloidin-Rhodamine (1500) 
and nuclei counterstained with DAPI (11000) followed by confocal 
fluorescent imaging using micro spinning disc confocal ImageXpress 
High-throughput Imaging System. Image J analysis was carried out on 
the blue channel (nuclei) for each of the samples. The perimeters of 
particles ranging from 10 to infinity pixel size were counted. Standard 
deviation across the mean for each of the samples was then plotted. 
Pooled standard deviation was calculated using the following formula; 
spooled =
̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅
(n1 − 1)s21 + (n2 − 1)s22 + … + (nk − 1)s2k
n1 + n2+… + nk − k
√
(1) 
n1, n2 = sample size of population 1, 2 nk = sample size of population 
k s1, s2 = sample standard deviation of population n1, n2sk = sample 
standard deviation of population k. 
2.9. Zeta potential measurements 
Adherent MCEC were incubated in the presence of PTX stent 
conditioned media for 30 min, 2 h and 12 h in separate cell culture 
plates. At the given time points the cells were harvested by trypsiniza-
tion. Cells pelleted by centrifugation were resuspended in 1 ml of growth 
media at a cell density 0.5 × 106 cells/ ml. Approximately 1 ml of each 
cell suspension was then transferred into the capillary zeta cell and zeta 
potential measurements were taken using Zetasizer Nano ZS (Malvern 
Instruments). The samples were kept at 37 ◦C using a heating block. All 
measurements were carried out using zeta (electrophoretic light scat-
tering) mode. The mean zeta potential was determined from 2 runs of 10 
measurements for each sample. The zeta (ξ) potential was calculated 
from the electrophoretic mobility based on the Smoluchowski equation, 
u = Eξ/η, where u is the measured electrophoretic mobility, ξ is zeta 
potential value; E is the dielectric constant and η is the viscosity of the 
electrolytic solution. 
2.10. Quantification of cellular concentrations 
To evaluate cellular uptake of free paclitaxel, MCEC grown in a T75 
flask were treated with paclitaxel “supplemented” growth media at 
approx. 70% confluency. To prepare this media, a 1 mM stock was first 
prepared by transferring 10 mg of PTX into 11.5 ml of growth media. To 
achieve a homogenous mixture, paclitaxel supplemented media was 
sonicated for 10 min and shaken at each 1-min interval using a vortex 
mixer. To achieve a final concentration of 0.1 mM corresponding to the 
theoretical concentration of PTX conditioned media, a 1 in 10 dilution 
was carried out with growth media followed by further sonication. 
When MCEC grown in a T75 flask were at approx. 70% confluence the 
growth media was replaced with 10 ml of 0.1 mM paclitaxel media. 
After 24 h of paclitaxel exposure, cells were washed three times with 
PBS, gently tapping the flask to dislodge PTX particles stuck to the flask 
surface during the washings. Cells were harvested and resuspended in 1 
ml of PBS with 30 μl used for cell counting with trypan blue. The cell 
suspension was pelleted at 1000 x g for 5 min. The supernatant was 
discarded and 1 ml of ethanol was added to the cell pellet followed by 
incubation on ice for 15 min. Probe sonication was used to break open 
the cells and to release the intracellularly bound paclitaxel. To collect 
the supernatant, the cell debris were pelleted at 5000 x g for 5 min 
followed by solvent evaporation at RT and addition of 200 μl ethanol to 
concentrate the sample. Presence of PTX was then detected using HPLC. 
Cellular uptake was determined in μg/cell. 
3. Results 
3.1. PTX coating release 
Difficulties associated with studying poorly soluble drugs used in 
coatings on medical devices such as stents often result in a poor corre-
lation with in vivo response. Here, a simple method for poorly soluble 
drug preparation in bio-relevant media is proposed. The surface coating 
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of Zilver PTX stent containing a 429 μg total target dose was released by 
sonication into cell culture growth media followed by 48 h incubation at 
37 ◦C, 5% CO2. To quantify the amount of PTX coating released from the 
stent surface, the mass change was measured. Here, the stent samples 
were weighed out before and after the conditioned media preparation 
with the average value for the released coating for three stent samples 
calculated to be 0.43 ± 0.01 mg, Table 1. The mean released quantity 
falls within the expected range of lower specification limit (LSL): 0.386 
mg and upper specification limit (USL): 0.461 mg PTX coating for 5 mm 
diameter, 40 mm length Zilver PTX stents (Fig. 1). It was not possible to 
quantify the PTX released into the media by chromatography due its 
solubility in the media being less than the HPLC PTX detection limit of 
0.5 μg/ml. 
3.2. PTX stent conditioned media content uniformity 
The low solubility of PTX in aqueous media means that it is often 
present as a suspension, making it difficult to have confidence in the 
concentrations that the cells are exposed to in the suspension aliquots. 
Thus, the content uniformity of the PTX stent conditioned media was 
validated by exposing MCEC (n = 25) to 200 μl aliquots of the prepared 
stent conditioned media, representing the total volume of media (5 ml) 
that had been incubated with the stent. After 48 h of cell incubation in 
the PTX stent conditioned media, formation of micronuclei in the treated 
samples is evident from confocal imaging as shown in Fig. 2. The vari-
ation in the nuclear perimeter caused by the presence of variously sized 
micronuclei was used to measure the content uniformity of the PTX stent 
conditioned media. Fig. 3 shows no significant difference between 
sample and control group in the mean perimeter. However, an increased 
nuclear perimeter variation was noted across the treated group 
compared to the control samples that exhibit a much tighter variance. 
This observation was depicted by following values for sample mean 
perimeter 52.15 ± 29.50 μm and controls 56.62 ± 10.46 μm, where 
variance is denoted by pooled standard deviation. Statistical analysis 
showed that the variances are equal, and no significant difference exists 
within the treatment group with the p > 0.05. To further determine 
whether the PTX stent conditioned media maintains its potency across 
all aliquots, cell viability was examined using an MTT assay, Fig. 4. The 
percentage cell viability was in a narrow range of 44.56% to 58.86% 
with 51.20 ± 4.03% mean viability. No significant differences were 
found within the samples (p > 0.05). Binding of PTX to plastics and glass 
containers and proteins has been reported under in vitro conditions 
(Song et al., 1996) but due to the high theoretical concentration 
compared to its solubility, PTX is present in the conditioned media as a 
suspension. Thus the resulting media is always saturated and as such 
would have a constant concentration, regardless of small amounts 
binding to the cell culture plastic or serum protein present. 
3.3. Cellular uptake of PTX 
Fully solubilized PTX easily penetrates the cell membranes and ex-
erts its mechanism of action by binding to microtubuli (Huizing et al., 
1995). When an aqueous solvent is used (which has a low solubility for 
PTX), such as cell culture media without the use of a solubilizing agent, 
much of the added PTX is present in suspension. In order to investigate 
the interactions of the PTX stent conditioned media with the MCEC, zeta 
potential measurements (Fig. 5) and high-performance liquid chroma-
tography (Table 2) were used to evaluate and quantify cellular uptake of 
PTX in the conditioned media. Zeta potential describes the potential at 
the surface of hydrodynamic shear as a result of electrostatic in-
teractions of cells or particles in a liquid (Zhang et al., 2008). Although, 
most typically used to assess cellular uptake of nanoparticles such as 
drug nanocarriers and other particle suspensions (Wyness et al., 2018; 
Jeon et al., 2018), zeta potential has also been utilized for cell adhesion 
and interaction studies with peptides (Maraming et al., 2019; Figueira 
et al., 2017; Torcato et al., 2013). Therefore, zeta potential of MCEC was 
evaluated in the presence of PTX suspensions such as that in PTX 
conditioned media to investigate the interactions with the endothelial 
model cell line. Zeta potential measurements were carried out at 30 min, 
2 h and 12 h after exposure to PTX stent conditioned media. Fig. 5 shows 
that exposing the MCEC to the PTX stent conditioned media for 30 min 
did not inflict a change in the zeta potential value when compared to the 
control, − 8.515 ± 0.135 mV and  − 8.525 ± 0.185 mV, respectively. 
Increasing the exposure time to 2 h resulted in a more negative zeta 
potential, indicating paclitaxel binding to the cell surface. The inter-
nalization, thus cellular uptake of the PTX is observed at the 12 h time 
point by a shift of zeta potential to a more positive value of − 8.430 ±
0.460 mV. 
To quantify the cellular uptake of PTX, adherent cells were treated 
with 0.1 mM PTX prepared directly in cell growth media. This concen-
tration relates back to the Zilver PTX stent that contains 429 μg of PTX 
total target coating, which is then released into 5 ml of aqueous media, 
0.1 mM. Cellular uptake expressed per 1 × 106 cells was found to be 
145.10 ± 12.33 μg. The actual concentration was determined to be 
286.59 ± 16.65 μg/ml corresponding to 66.80% cellular uptake of total 
target PTX quantity (429 μg) that would be present in 5 ml of stent 
conditioned media. 
3.4. PTX stent conditioned media viability vs PTX in DMSO 
Fig. 6 shows the percentage viability of MCEC cells exposed to free 
paclitaxel present in the stent conditioned media and DMSO dissolved 
PTX at 48 h. Unlike the PTX stent conditioned media with 100 μM 
theoretical concentration, which suppresses cells growth (48.0 ± 3.6% 
viability), the 100 μM DMSO dissolved PTX induced severe cytotoxic 
effects with practically no viability (3± 1%) at 48 h. The 48% viability of 
cells treated with the PTX conditioned media falls between the con-
centration range of 0.1–1 μM PTX in DMSO, indicating at least a 100 fold 
lower concentration than the theoretical 100 μM concentration. To 
confirm the cytotoxicity effects seen with PTX conditioned media, the 
viability assay was carried out with filtered and diluted PTX conditioned 
media. Diluting the filtered PTX conditioned media resulted in lower 
cytotoxicity as expected, while the filtered PTX conditioned media 
exhibited the same cytotoxicity as unfiltered PTX conditioned media 
(supplementary information). Fig. 7(A) shows representative images of 
MCEC treated with 100 μM PTX in DMSO with apparent presence of 
circular cells, indicating loss of viability, surrounded by needle-like 
paclitaxel structures. In Fig. 7(B), PTX crystal-like particles present in 
the conditioned media lie on top of a cell layer (cells not seen in the 
image). Formation of micronuclei in Fig. 8 shows that the PTX stent 
conditioned media induces the same response on a subcellular level as 
the 1 and 0.1 μM concentrations that were identified as the theoretical 
concentration range of PTX in aqueous media. 
4. Discussion 
A literature survey revealed that hydrophobic drugs, such as pacli-
taxel, are typically pre-dissolved in DMSO in biological assays (Williams 
et al., 2013). However, this approach leads to artificially high doses of 
drug not representative of in vivo concentrations, resulting in non- 
Table 1 
Quantity of the PTX coating released from the Zilver PTX drug eluting stent after 
the preparation of the stent conditioned media as determined from stent mass 
change. ‘Before’ represents initial stent weight including PTX coating and ‘after’ 
represents bare stent weight.  
Target coating weight: 0.429 mg LSL: 0.386 mg, USL: 0.461 mg 
Stent Sample Weight Before (mg) Weight After (mg) Coating Released (mg) 
1 154.80 154.35 0.45 ± 0.01 
2 153.60 153.17 0.43 ± 0.01 
3 153.33 152.91 0.42 ± 0.01  
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representative compromised cellular functions. To study hydrophobic 
drugs in bio-relevant media, especially those used for stent coatings, a 
simple and reproducible method was developed and validated in this 
study. In order to release the PTX coating from the stent surface, the 
stent samples were sonicated directly in cell growth media followed by 
incubation at 37 ◦C, 5% CO2. The approach described herein was 
inspired by the ISO 10993-5 standard “Biological Evaluation of Medical 
Devices” used during the in vitro biocompatibility testing of medical 
devices prior to animal studies. The standard recommends that the 
extraction occurs at 37 ◦C for 24 to 72 h using mammalian cell culture 
media supplemented with 5–10% serum, to extract both hydrophilic and 
hydrophobic substances (A. Food and Drug, 2017). 
Fig. 1. Optical reflection images taken of Zilver PTX drug eluting stent strut surface before (PTX coated) and after (uncoated) preparation of the PTX stent 
conditioned media. Scale bars = 500 μm. 
Fig. 2. Representative confocal images of MCEC treated or untreated with the PTX stent conditioned media. Cytoskeletal f-actin filaments are stained with 
Phalloidin-Rhodamine (red) and nuclei are counterstained with DAPI (blue). Monochromatic images show individual blue and red channels in grayscale. Scale bars 
= 100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Paclitaxel, coated on the Zilver PTX vascular stent, is a highly hy-
drophobic drug, with very low solubility in aqueous media, ~ 1 μg/ml 
(Gi et al., 2004). Due to its poor solubility, during the preparation of 
stent conditioned media as proposed in this study, the majority of the 
PTX from the stent is most likely to be suspended in the media. With the 
small volume aliquots of the stent conditioned media used in cell assays, 
the homogeneity of the PTX-media suspension needed to be validated. 
Variation in the nuclear perimeter was selected as one of the validation 
parameters as paclitaxel is known to induce micronucleation in cells at 
nM concentrations (Mitchison et al., 2017), thus providing a picture on 
the paclitaxel solubility and potency in a water based medium. The 
fluorescent images in Fig. 2 show formation of micronuclei in the treated 
group especially evident from the blue channel and demonstrated by an 
almost 3-fold increase in pooled variation of the mean nuclear perimeter 
52.15 ± 29.50 μm in the samples treated with stent conditioned media 
compare to 56.62 ± 10.46 μm in cells treated just with media. Thus there 
is consistency in the PTX content of the stent conditioned media sample 
aliquots (n = 25) to induce variances in the perimeters of nuclei as a 
result of micronuclei formation that is induced by genotoxic response to 
the paclitaxel exposure. The cell viability results across 25 samples, each 
treated with 200 μl of the PTX stent conditioned media showed a low- 
level variation in viability with the mean value of 51.02 ± 4.03%, 
demonstrating consistency in the aliquot potency of the PTX stent 
conditioned media to inflict reduced cell proliferation due to the pres-
ence of PTX. Unfortunately, the PTX concentration in the conditioned 
media is below the limit of HPLC detection. Nevertheless, both valida-
tion methods revealed no significant difference within the treatment 
groups (p > 0.05) confirming the use of PTX stent conditioned media as a 
valid tool for evaluating the biocompatibility of the paclitaxel stent 
coating in cellular assays. 
Fig. 3. Variation in the perimeter of MCEC nuclei; samples 
1–25 represent cells treated with PTX stent conditioned media; 
samples C1-C3 represent control cells without any treatment. 
Cells with and without treatment were cultured for 48 h. After 
48 h cell samples were stained and nuclear perimeter was 
quantified using the blue channel (DAPI) with Image J soft-
ware. Variances of the treatment group p value > 0.05. Error 
bars represent standard deviation. Experiment carried out in 
duplicates. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of 
this article.)   
Fig. 4. Content uniformity of the PTX stent conditioned media volume tested across 25 samples using cell viability as a measured response. The line graph shows 
percentage viability of MCEC with respect to control treated with 200 μl PTX stent conditioned media per sample as determined by MTT assay after 48 h of exposure. 
Reference line is plotted at the overall mean 51.20%. Overall SD: 4.03%. 
Fig. 5. Zeta potential measurements as determined by exposure of MCEC to 
PTX stent conditioned media for 30 min, 2 h and 12 h. Trypsinized cells were 
re-suspended in the PTX stent conditioned media at a density of 0.5 × 106 cells/ 
ml. Measurements taken using Zetasizer Nano ZS (Malvern Instruments). Error 
bars represent standard deviation. 
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Solubilized paclitaxel, such as the DMSO dissolved PTX used in this 
study, is known to enter and accumulate in tissues (Wiernik et al., 1987), 
targeting intracellular microtubules. To investigate how the PTX stent 
conditioned media will interact with cells, zeta potential measurements, 
which describe cell surface electrostatics and can be used for adhesion 
and interaction studies, were conducted (Zhang et al., 2008; Zhang 
et al., 2009; Wilhelm et al., 2002). Based on the increase in electro-
negativity, the PTX in the stent conditioned media appears to interact 
with the negative cell surface upon 2 h exposure in the culture and is 
taken up by the cells at 12 h as demonstrated by the subsequent decrease 
in electronegativity in Fig. 5 (Selvi et al., 2012). 
The theoretical concentration 100 μM of the PTX stent conditioned 
media was calculated from the total target mass of PTX in 5 ml of 
conditioned media. However, it was expected that due to its’ poor sol-
ubility in aqueous media, a large fraction of PTX would be in suspension 
rather than in solution, resulting in a lower effective concentration. This 
expectation was demonstrated by 48% cell growth for the PTX stent 
conditioned media at 100 μM theoretical concentration, while the same 
concentration of PTX in DMSO exhibited severe cytotoxic effects with 
3% cell growth at 48 h. In fact, the 100 μM PTX in DMSO concentration 
was so high that the PTX crystalized into needle-like particles, a phe-
nomenon previously described in the literature (Foss et al., 2008), as 
seen in Fig. 7(A). As mentioned above, the molar concentration of the 
soluble fraction of PTX in the cell culture medium could not be analyt-
ically quantified due to being below the detection limit of the HPLC, 0.5 
μg/ml. Thus, the molar concentration was estimated from a comparison 
of PTX stent conditioned media cell growth results (48%) to those of PTX 
in DMSO (Fig. 6) and found to fall between 1 and 0.1 μM (45%, 59%). 
Correlating the estimated PTX concentration from the viability assay to 
the PTX HPLC detection limit of 0.5 μg/ml or 0.59 μM, the actual con-
centration of the soluble fraction in the PTX stent conditioned media, 
appears to lie between 0.59 and 0.1 μM. 
PTX, an anti-mitotic drug, supresses cell proliferation by binding to 
microtubuli during cell mitosis (Schiff and Horwitz, 1980; Wall and 
Wani, 1995). As a result paclitaxel treated cells experience prolonged 
mitotic arrest (Lara-Gonzalez et al., 2012; Musacchio, 2015; Uetake 
et al., 2007). Cells exposed to prolonged mitotic arrest can often undergo 
a return to the interphase without proper chromosome segregation, 
leading to the formation of micronuclei. This phenomenon was well 
described for paclitaxel (Rieder and Maiato, 2004). The formation of 
micronuclei, that occurs at nanomolar concentration of PTX and is un-
likely to occur at higher concentrations as cells would die during mitosis 
or in the subsequent cell cycle if exited from prolonged mitotic arrest, 
was confirmed for PTX conditioned media and the 0.1 and 1 μM PTX in 
DMSO from fluorescent imaging (Rieder and Maiato, 2004; Jordan et al., 
1996), supporting the claim that the PTX stent conditioned media is 
suitable for cell-based assays and may provide a better model of the in 
vivo response. 
5. Conclusions 
In summary, the use of organic solvents to dissolve extremely hy-
drophobic drugs coatings from stents during in vitro cell culture studies 
has been compared with a novel stent conditioned media approach. PTX 
coated on drug eluting stents, intended for vascular applications, was 
used in this study. A simple method for preparation of a hydrophobic 
drug suspension of PTX desorbed from the stent in bio-relevant media, 
Table 2 
Intracellular uptake of the PTX by MCEC at 24 h as quantified by HPLC.  
Cell Count Peak Area Calculated Concentration (μg/ml) Dilution Actual Concentration (μg/ml) Concentration per 1 × 106 cells (μg) 
2,400,000 972.30 61.87 5.00 309.33 128.89 
1,900,000 895.25 56.11 5.00 280.54 147.65 
1,700,000 866.76 53.98 5.00 269.90 158.77 
x‾ 286.59 ± 16.65 μg/ml 145.10 ± 12.33 μg 
Fig. 6. Percentage proliferation of MCEC with respect to control treated with a 
PTX stent conditioned media and a range of concentrations of DMSO dissolved 
PTX at 48 h. 
Fig. 7. Representative images of MCEC treated with 100 μM paclitaxel in DMSO (A) and in PTX stent conditioned media (B) as captured by phase contrast optical 
microscopy at 48 h. Scale bars: 500 μm. 
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without the use of organic solvents to pre-dissolve the drug was devel-
oped. This ‘PTX stent conditioned media’ preparation was validated in 
terms of content uniformity and potency for in vitro assay use. It was 
shown that using DMSO to solubilise the PTX leads to distinctively 
different cellular responses than the PTX stent conditioned media. PTX 
stent conditioned media, 100 μM theoretical concentration, is taken up 
by MCEC and results in similar growth cell suppression as 0.1 μM DMSO 
dissolved PTX. PTX released from the stent surface was used as a model 
drug but this method can be extended to other hydrophobic drugs. In 
vivo studies need to be conducted to test if the stent conditioned media 
gives better in vitro/in vivo data correlation than when organic solvents 
are used as solubilizers. 
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